Medicaid Prior Authorization Policies for Medication Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Young Children: A Comprehensive Review

Abstract

Attention-Deficit/Hyperactivity Disorder (ADHD) is one of the most common neurodevelopmental disorders affecting young children. While evidence supports behavioral therapy as the first-line treatment for ADHD in children under six, medications such as stimulants are also prescribed. Medicaid, which provides health insurance to many children in the United States, has implemented prior authorization (PA) policies to regulate the use of medication for ADHD in young children. This review explores the structure and impact of Medicaid PA policies, their influence on medication usage, and the barriers and benefits associated with these policies. The role of Medicaid in promoting evidence-based care and behavioral interventions is also discussed.

Received Date: July 08, 2024                  Accepted Date: July 29, 2024            

Published Date: August 01, 2024

Available Online at: https://www.ijsrisjournal.com/index.php/ojsfiles/article/view/300

DOI: https://doi.org/10.5281/zenodo.14583564